Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Andreasen

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 28, 2003
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitorsL Parnetti, S Amici, A Lanari, et al.
Archives of General Psychiatry|February 1, 1986
Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging studyN Andreasen, H A Nasrallah, V Dunn, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 29, 2000
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasmaH Vanderstichele, E Van Kerschaver, C Hesse, et al.
Journal of Internal Medicine|March 11, 2014
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014L S Schneider, F Mangialasche, N Andreasen, et al.
Acta Neurologica Scandinavica|October 1, 2010
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's diseaseL Parnetti, D Chiasserini, U Andreasson, et al.
Journal of Neuroscience Research|April 22, 2003
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's diseaseJ Sáez-Valero, L R Fodero, M Sjögren, et al.
Molecular Psychiatry|December 31, 2003
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairmentH Hampel, S J Teipel, T Fuchsberger, et al.
Dementia and Geriatric Cognitive Disorders|February 21, 2007
Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methodsA H Simonsen, S F Hansson, U Ruetschi, et al.
Clinical Chemistry|September 25, 2001
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference valuesM Sjögren, H Vanderstichele, H Agren, et al.
Psychological Medicine|October 15, 2010
Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive featuresB Crespo-Facorro, R Roiz-Santiáñez, R Pérez-Iglesias, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 28, 2003
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitorsL Parnetti, S Amici, A Lanari, et al.
Archives of General Psychiatry|February 1, 1986
Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging studyN Andreasen, H A Nasrallah, V Dunn, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 29, 2000
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasmaH Vanderstichele, E Van Kerschaver, C Hesse, et al.
Journal of Internal Medicine|March 11, 2014
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014L S Schneider, F Mangialasche, N Andreasen, et al.
Acta Neurologica Scandinavica|October 1, 2010
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's diseaseL Parnetti, D Chiasserini, U Andreasson, et al.
Journal of Neuroscience Research|April 22, 2003
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's diseaseJ Sáez-Valero, L R Fodero, M Sjögren, et al.
Molecular Psychiatry|December 31, 2003
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairmentH Hampel, S J Teipel, T Fuchsberger, et al.
Dementia and Geriatric Cognitive Disorders|February 21, 2007
Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methodsA H Simonsen, S F Hansson, U Ruetschi, et al.
Clinical Chemistry|September 25, 2001
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference valuesM Sjögren, H Vanderstichele, H Agren, et al.
Psychological Medicine|October 15, 2010
Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive featuresB Crespo-Facorro, R Roiz-Santiáñez, R Pérez-Iglesias, et al.
Pageof 8